Skip to main content
Premium Trial:

Request an Annual Quote

Schering-Plough Licenses Oncomethylome Sciences Assay to Study Temodar Therapy

NEW YORK, Nov. 16 (GenomeWeb News) - Schering-Plough will license pharmacogenomic assay technology from Oncomethylome Sciences to study DNA methylation status in brain cancer patients, the companies said today.

 

Schering-Plough will pay OMS an upfront license payment, milestone payments, and sample processing fees. Actual amounts were not disclosed. 

 

Under the agreement, Schering-Plough will receive a worldwide non-exclusive license to use the assays and technology to measure the methylation status of the MGMT gene in brain cancer patients being treated with its drug Temodar. The collaboration will focus on glioblastoma multiforme brain cancer, but can potentially expand to other cancers and products.

 

OMS is a privately held company based in Belgium.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.